LUMOSA THERAPEUTICS CO., LTD.
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.lumosa.com.tw
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT05403866
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT05198323
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04809818
- Locations
- 🇺🇸
Lumosa Phase 1 Unit, Cypress, California, United States
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT04393675
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04256434
- Locations
- 🇺🇸
WCCT Global Inc., Cypress, California, United States
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04091945
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇺🇸Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States
🇺🇸JFK Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States
A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 221
- Registration Number
- NCT02468128
- Locations
- 🇨🇳
Chang Gung Memorial Hospital at Chiayi, Putzu City, Chiayi Hsien, Taiwan
🇨🇳Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung City, Taiwan
🇨🇳Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan
A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Lumosa Therapeutics Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02446301
- Locations
- 🇨🇳
Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
© Copyright 2024. All Rights Reserved by MedPath